Epidermal growth factor receptor inhibitors: a patent review (2010 – present)

Bibliography

• Yarden Y, Sliwknowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-37
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ErbB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54
   PubMed Web of Science ®Google Scholar
• Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265:1093-5
   PubMed Web of Science ®Google Scholar
• Ward WHJ, Cook PN, Slater AM, et al. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 1994;48:659-66
   PubMed Web of Science ®Google Scholar
• Bridges AJ, Zhou H, Cody DR, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure activity relationship for analogues of 4-(3-bromo-anilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem 1996;39:267-76
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319(9):525-32
   PubMed Web of Science ®Google Scholar
• Vivanco I, Mellinghoff IK. Epidermal growth factor receptor inhibitors in oncology. Curr Opin Oncol 2010;22(6):573-8
   PubMedGoogle Scholar
• Iwata K, Miller PE, Barbacci EG, et al. CP-358, 774: a selective EGFR kinase inhibitor with potent antiproliferative activity against HN5 head and neck tumor cells [abstract 4248]. Proc Am Assoc Cancer Res 1997;38:633-4
   Google Scholar
• Woodburn JR, Barker AJ, Gibson KH, et al. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development [abstract 4251]. Proc Am Assoc Cancer Res 1997;38:633-4
   Google Scholar
• Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652-9
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:1-11
   Google Scholar
• Carmi C, Lodola A, Rivara S. Epidermalgrowth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion. Mini Rev Med Chem 2011;11:1019-30
   PubMedGoogle Scholar
• Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070-4
   PubMed Web of Science ®Google Scholar
• Garuti L, Roberti M, Bottegoni G. Irreversible protein kinase inhibitors. Curr Med Chem 2011;18:2981-94
   PubMed Web of Science ®Google Scholar
• Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105:2070-5
   PubMed Web of Science ®Google Scholar
• Smaill JB, Rewcastle GW, Loo JA, et al. Tyrosine kinase inhibitors: 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem 2000;43:1380-97
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11
   PubMed Web of Science ®Google Scholar
• Tsou HR, Overbeek-Klumpers EG, Hallett WA, et al. Optimization of 6,7- disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem 2005;48:1107-31
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu F, Gale CM, et al. PF00299804, an irreversible Pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924-92
   PubMed Web of Science ®Google Scholar
• Li DD, Hou YP, Wang W, et al. Exploration of chemical space based on 4-anilinoquinazoline. Curr Med Chem 2012;19:871-92
   PubMedGoogle Scholar
• Adriana C, Maria TC, Giovanni M, et al. Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold. J Med Chem 2010;53:1862-6
   PubMedGoogle Scholar
• Boehringer Ingelheim International Gmbh. Preparation of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxyquinazoline-6-yloxy]-1,4-diazaspiro[5.5]undecan-5-one dimaleate as EGFR inhibitors. WO104206; 2012
   Google Scholar
• ICCAS. Quinazoline derivatives as EGFR inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. CN102452988; 2012
   Google Scholar
• Boehringer Ingelheim International Gmbh. Procédé de synthèse stéréosélective de 9-hydroxy-5-oxo-1,4-diaza-spiro [5.5] undécanes qui sont 1,4-protégés. WO117568; 2013
   Google Scholar
• Curis, Inc. Quinazoline based EGFR inhibitors. US8349856; 2013
   Google Scholar
• Vijaykumar G, Pawar ML, Sos HB, et al. Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. J Med Chem 2010;53:2892-901
   PubMedGoogle Scholar
• Michalczyk A, Klüter S, Rode HB, et al. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. Bioorg Med Chem 2008;16:3482-8
   PubMedGoogle Scholar
• Caterina C, Andrea C, Stefano V, et al. Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion. J Med Chem 2010;53:2038-50
   PubMedGoogle Scholar
• Caterina C, Elena G, Federica V, et al. Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides J Med Chem. 2012;55:2251-64
   Google Scholar
• Bikker JA, Brooijmans N, Wissner A, et al. Kinase domain mutations in cancer: implications for small molecule drug design strategies. J Med Chem 2009;52:1493-509
   PubMed Web of Science ®Google Scholar
• Li HQ, Li DD, Lu X, et al. Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity. Bioorg Med Chem 2012;20:317-23
   PubMedGoogle Scholar
• Xu YY, Li SN, Yu GJ, et al. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity. Bioorg Med Chem 2013;21:6084-91
   PubMed Web of Science ®Google Scholar
• Ban SH, Usui T, Nabeyama W, et al. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase. Org Biomol Chem 2009;7:4415-27
   PubMed Web of Science ®Google Scholar
• Potashman MH, Duggan ME. Covalent modifiers: an orthogonal approach to drug design. J Med Chem 2009;2:1231-46
   Google Scholar
• Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;05:2070-5
   Google Scholar
• Blair JA, Rauh D, Kung C, et al. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol 2007;3:229-38
   PubMed Web of Science ®Google Scholar
• Hutchison Medipharma Enterprises Ltd. Preparation of quinazoline derivatives as inhibitors of epidermal growth factor receptors for treating tumor. CN101619043; 2010
   Google Scholar
• Hutchison Medipharma Enterprises Ltd. Quinazoline-1,6-diamine derivatives as EGFR inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO002845; 2010
   Google Scholar
• Zhejiang Beta Pharma, Inc. Icotinib hydrochloride as EGFR inhibitors and its preparation, crystallographic forms, pharmaceutical compositions and use in the treatment of cancers. WO003313; 2010
   Google Scholar
• Qilu Pharmaceutical Co. Ltd. 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors. WO030540; 2011
   Google Scholar
• Hangzhou Minsheng Pharmaceutical Co. Ltd. Preparation of quinazoline derivatives as EGFR inhibitors for treating cancer. WO017073; 2013
   Google Scholar
• Siavosh M, Andreas S, Matthias W, et al. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity. J Med Chem 2010;53:8546-55
   PubMedGoogle Scholar
• Sos ML, Rode HB, Heynck S, et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 2010;70:868-74
   PubMed Web of Science ®Google Scholar
• Kim Y, Ko J, Cui Z, et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther 2012;11:784-91
   PubMed Web of Science ®Google Scholar
• Ercan D, Zejnullahu K, Yonesaka K, et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010;29:2346-56
   PubMed Web of Science ®Google Scholar
• Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070-4
   PubMed Web of Science ®Google Scholar
• Zhou W, Ercan D, Janne P, et al. Discovery of selective irreversible inhibitors for EGFRT790M. Bioorg Med Chem Lett 2011;21:638-43
   PubMed Web of Science ®Google Scholar
• Chang SH, Zhang LW, Xu SL, et al. Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790 -Methionine790 Mutant. J Med Chem 2012;55:2711-23
   PubMed Web of Science ®Google Scholar
• Guangzhou Institute Of Biomedicine And Health. Pyrimidopyrimidone derivatives as EGFR inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancers. WO167415; 2012
   Google Scholar
• Tomoyasu I, Masaki S, Hiroshi B, et al. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem 2011;54:8030-50
   PubMedGoogle Scholar
• Youichi K, Hiroshi B, Tomohiro O, et al. Design and synthesis of pyrrolo[3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: exploration of novel back-pocket binders. J Med Chem 2012;55:3975-91
   PubMedGoogle Scholar
• Yang J, Wang LJ, Liu JJ, et al. Structural optimization and structure−activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations. J Med Chem 2012;55:10685-99
   PubMedGoogle Scholar
• Coumar MS, Chu CY, Lin CW, et al. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. J Med Chem 2010;53:4980-8
   PubMed Web of Science ®Google Scholar
• Wu CH, Coumar MS, Chu CY, et al. Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and michael acceptor group for maximal potency. J Med Chem 2010;53:7316-26
   PubMed Web of Science ®Google Scholar
• Zhou W, Liu X, Tu Z, et al. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant. J Med Chem 2013;56:7821-37
   PubMedGoogle Scholar
• Elzahabi HAS. Synthesis, characterization of some benzazoles bearing pyridine moiety: search for novel anticancer agents. Eur J Med Chem 2011;46:4025-34
   PubMed Web of Science ®Google Scholar
• Hu WP, Chen YK, Liao CC, et al. Synthesis, and biological evaluation of 2-(4-aminophenyl)benzothiazole derivatives as photosensitizing agents. Bioorg Med Chem 2012;46:6197-207
   Google Scholar
• Lin RH, Johnson SG, Connolly PJ, et al. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors Bioorg Med Chem Lett. 2009;19:2333
   Google Scholar
• Malleshappa NN, Harun M, Kaur PM, et al. Benzothiazoles: search for anticancer agents. Eur J Med Chem 2012;54:447-62
   PubMedGoogle Scholar
• Lv PC, Wang KR, Yang Y, et al. Synthesis and biological evaluation of novel thiazole derivatives as potent FabH inhibitors. Bioorg Med Chem Lett 2009;19:6750-4
   PubMed Web of Science ®Google Scholar
• Gnewuch CT, Sosnovsky GA. Critical appraisal of the evolution of N-nitrosoureas as anticancer drugs. Chem Rev 1997;97:829-1013
   PubMed Web of Science ®Google Scholar
• Okada H, Koyanagi T, Yamada N, et al. Synthesis and antitumor activities of prodrugs of benzoylphenylureas. Chem Pharm Bull 1994;42:57-61
   PubMedGoogle Scholar
• Jiang JD, Denner L, Ling YH, et al. Double blockade of cell cycle at G1-S transition and M phase by 3-Iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand. Cancer Res 2002;52:6080-8
   Google Scholar
• Dai Y, Guo Y, Frey RR, et al. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J Med Chem 2005;48:6066-83
   PubMed Web of Science ®Google Scholar
• Dai Y, Hartandi K, Ji Z, et al. Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem 2007;50:1584-97
   PubMed Web of Science ®Google Scholar
• Li HQ, Yan T, Lv PC, et al. Urea derivatives in anticancer agents. Anti Cancer Agents Med Chem 2009;9(4):471-80
   PubMedGoogle Scholar
• Li HQ, Yan T, Yang Y, et al. Synthesis and structure–activity relationships N-benzyl-N-(X-2-hydroxybenzyl)-N′-phenylureas and thioureas as antitumor agents. Bioorg Med Chem 2010;18:305-13
   PubMed Web of Science ®Google Scholar
• Lv PC, Li HQ, Sun J, et al. Synthesis and biological evaluation of pyrazole derivatives containing thiourea skeleton asanticancer agents. Bioorg Med Chem 2010;18:4606-14
   PubMed Web of Science ®Google Scholar
• Universita' Degli Studi Di Parma. Irreversible egfr inhibitor compounds with antiproliferative activity. WO076764; 2010
   Google Scholar
• Pontier SM, Huck L, White DE, et al. Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. Oncogene 2010;29:3374-85
   PubMed Web of Science ®Google Scholar
• Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof. US0249092; 2010
   Google Scholar
• Avila Therapeutics, Inc. Mutant-selective EGFR inhibitors for treatment of Cancer. WO064706; 2012
   Google Scholar
• Zuo M, Zheng YW, Lu SM, et al. Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC–EGFR dual inhibitors. Bioorg Med Chem 2012;20:4405-12
   PubMed Web of Science ®Google Scholar
• Lee SL, Hsu EC, Chou CC, et al. Identification and characterization of a novel integrin-linked kinase inhibitor. J Med Chem 2011;54:6364-74
   PubMedGoogle Scholar
• Abou-Seri SM. Synthesis and biological evaluation of novel 2,40-bis substituted diphenylamines as anticancer agents and potential epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem 2010;45:4113-21
   PubMed Web of Science ®Google Scholar
• Ongarora BG, Fontenot KR, Hu K, et al. Phthalocyanine−peptide conjugates for epidermal growth factor receptor targeting. J Med Chem 2012;55:3725-38
   PubMedGoogle Scholar
• Carmi C, Mor M, Petronini PG, et al. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem Pharmacol 2012;84:1388-99
   PubMed Web of Science ®Google Scholar
• Efferth T. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. Curr Med Chem 2012;19:5735-44
   PubMed Web of Science ®Google Scholar
• Vivanco I, Mellinghoff IK. Epidermal growth factor receptor inhibitors in oncology. Curr Opin Oncol 2010;22:573-8
   PubMedGoogle Scholar
• Tjeerd B, Allard K. Irreversible protein kinase inhibitors: balancing the benefits and risks. J Med Chem 2012;55:6243-62
   PubMedGoogle Scholar
• Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012;75:311-35
   PubMed Web of Science ®Google Scholar